Nefrologia
#ESCCongress | Estudo randomizado por clusters: entre pacientes com risco aumentado para AVC, um substituto do sal (75% de cloreto de sódio e 25% de cloreto de potássio) reduziu as taxas de AVC, os eventos cardiovasculares e a morte por qualquer causa.
30 Ago, 2021 | 13:23hEffect of Salt Substitution on Cardiovascular Events and Death – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Low-sodium salt prevents stroke – European Society of Cardiology
Comentário: Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD – TCTMD
Comentário no Twitter
SSaSS: In RCT that compared salt substitute w/ regular salt, rates of stroke, major CV events, death lower with salt sub. #ESCCongress https://t.co/Yt6vMrYSDh pic.twitter.com/jtymS36zqs
— NEJM (@NEJM) August 29, 2021
#ESCCongress | Estudo randomizado: finerenona reduziu os eventos cardiovasculares em pacientes com doença renal e diabetes tipo 2 (12,4% vs. 14,2% durante um seguimento médio de 3,4 anos), mas o risco de hiperpotassemia foi aumentado (10,8% vs. 5,3%).
30 Ago, 2021 | 13:16hComunicado de imprensa: Finerenone benefits patients with diabetes across spectrum of kidney disease – European Society of Cardiology
Comentários:
Conteúdo relacionado: [Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes
Comentário no Twitter
FIGARO-DKD: Among patients with stage 1 to 4 CKD and T2 diabetes, finerenone improved CV outcomes as compared with placebo. #ESCCongress https://t.co/mcfmvftBvy pic.twitter.com/qizit80NBa
— NEJM (@NEJM) August 28, 2021
#ESCCongress | Estudo randomizado: tratamento inicial da hipertensão com uma única pílula composta por 4 drogas com um quarto da dose (irbesartana 37,5 mg, anlodipino 1,25 mg, indapamida 0,625 mg e bisoprolol 2,5 mg) atingiu uma redução melhor da pressão arterial vs. monoterapia padrão (irbesartana 150 mg).
30 Ago, 2021 | 13:12hInitial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial – The Lancet (link para o resumo – $ para o texto completo)
Comentário: Quadruple UltrA-low-dose tReaTment for hypErTension – QUARTET – American College of Cardiology
Nova diretriz da OMS sobre o tratamento farmacológico da hipertensão em adultos.
26 Ago, 2021 | 12:29hGuideline for the pharmacological treatment of hypertension in adults – World Health Organization
Conteúdo relacionado: WHO: More than 700 million people with untreated hypertension – Number of people living with hypertension has doubled to 1.28 billion since 1990.
Comentário no Twitter (fio – clique para saber mais)
The number of adults aged 30-79 living with #hypertension has doubled from 650 million to 1.28 billion since 1990, according to a 🆕 comprehensive global 🌎🌍🌏 analysis of trends in hypertension prevalence, detection, treatment and control.
👉 https://t.co/MI48CX2kEO pic.twitter.com/ARpS8uipeY
— World Health Organization (WHO) (@WHO) August 25, 2021
Tendências mundiais na prevalência de hipertensão e progresso no tratamento e no controle entre 1990 e 2019: uma análise agrupada de 1.201 estudos de representatividade populacional com 104 milhões de participantes.
25 Ago, 2021 | 13:14hComentário: Global and national high blood pressure burden and control – The Lancet (necessário cadastro gratuito)
Comentário no Twitter
Our new analysis within #NCDRisC on the #worldwide #hypertension #prevalence in last 30 yrs published in @TheLancet. The number of people with HTN doubled from 1990 with 626 million🕴️♀️ and 652 million 🕴️ in 2019. Control rates were ⬇️10% in some countries!https://t.co/FdjusD38X3 pic.twitter.com/famYphfqC8
— Maciej Banach (@maciejbanach) August 25, 2021
Estudo randomizado | Ablação suprarrenal baseada em cateter reduz o aldosteronismo primário.
25 Ago, 2021 | 13:07hCatheter-Based Adrenal Ablation Remits Primary Aldosteronism: A Randomized Medication-Controlled Trial – Circulation (gratuito por tempo limitado)
Comentário no Twitter
#ResearchLetter: RCT data show catheter-based adrenal ablation effectively ⬇️ BP in primary aldosteronism comparable to spironolactone – A potential therapy for patients unable to tolerate medications? https://t.co/ImSAdnVtxE #AHAJournals pic.twitter.com/WSJjFpzKPo
— Circulation (@CircAHA) August 21, 2021
Revisão | Hiponatremia aguda e crônica.
25 Ago, 2021 | 13:05hAcute and Chronic Hyponatremia – Frontiers in Medicine
Conteúdos relacionados:
Podcast: Hyponatremia deconstructed
Guidelines for the Management of Exercise-Associated Hyponatremia
Coisas que fazemos sem motivo nenhum: suspensão rotineira de metformina no hospital.
25 Ago, 2021 | 13:00hEstudo randomizado | Suplementação de vitamina D não tem efeito sobre a função renal de adultos pré-diabéticos.
25 Ago, 2021 | 12:58hEffect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial – Clinical Journal of the American Society of Nephrology (link para o resumo – $ para o texto completo)
Comentário no Twitter
Low circulating 25-hydroxyvitamin D concentration has been suggested as a risk factor for both type 2 diabetes and kidney disease. This study found that in persons with prediabetes, vitamin D supplementation did not affect progression of KDIGO risk scores https://t.co/e1EmP403TD pic.twitter.com/yEQjrvZr7A
— CJASN (@CJASN) August 24, 2021
Estudo randomizado | Inibidores de SGLT2 reduzem o risco de hiperpotassemia em pacientes com diabetes e doença renal crônica.
24 Ago, 2021 | 11:36hEffects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal (link para o resumo – $ para o texto completo)
Comentário no Twitter
SGLT2 inhibition reduces the risk of serious hyperkalemia in people with diabetic kidney disease, which may enable greater use of RAAS inhibitors in CKD and/or heart failure
New CREDENCE data presented this week at #ESCCongress, now in @ESC_Journals:https://t.co/OEqnXTdBDi pic.twitter.com/zsanEFZVCy
— Brendon Neuen (@brendonneuen) August 23, 2021